Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.0001 USD 0.00(0%)
Last update at 2026-10-26T20:00:00Z
VOLUME
442968
Market Cap
2.75M

Momentum Score

…

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Deltagen Inc (DGEN.US) is quoted on the OTC Pink market but public disclosures and current filings do not clearly describe the company's core business or operations. Because verifiable operating details are scarce, long-term growth drivers cannot be confirmed; any potential upside depends on future disclosure, proven revenue generation and audited financial reporting, which may benefit investors if delivered.
Material risks include limited disclosure and absence of audited financials, low trading liquidity and high share-price volatility, regulatory or delisting risk and difficulty assessing management and financial condition.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.77M
Revenue Per Share
-
Gross Profit TTM
0.77M
Debt / Equity
-
ROE
-2.72%
Net Debt
-3.53M
ROCE
-2.75%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Income before tax -0.05M 0.16M -4.42M -1.17M -0.69M
Minority interest 0.00M 0.00M 0.00M 0.00M -
Net income -0.05M 0.16M -4.42M -1.17M -0.69M
Selling general administrative 0.00M 0.00M 0.00M 0.00M -
Gross profit 0.77M 0.77M 0.66M 0.71M -
Ebit -0.05M 0.16M 0.11M 0.00M -0.69M
Ebitda - - - - -0.67M
Depreciation and amortization - - - - 0.01M
Operating income -0.05M 0.16M 0.11M 0.00M -0.69M
Other operating expenses 0.81M 0.61M 0.55M 0.71M 2.68M
Interest expense 0.00M 0.00M 0.00M 0.00M -
Extraordinary items 0.00M 0.00M 0.00M 0.00M -
Non recurring 0.00M 0.00M 0.00M 0.00M -
Other items 0.00M 0.00M 0.00M 0.00M -
Income tax expense 0.00M 0.00M 0.00M 0.00M -
Total revenue 0.77M 0.87M 1.02M 1.05M 1.99M
Total operating expenses 0.82M 0.71M 0.91M 1.05M 2.67M
Cost of revenue 0.00M 0.10M 0.36M 0.34M -
Total other income expense net 0.00M 0.00M -4.53M -1.17M 0.01M
Discontinued operations 0.00M 0.00M 0.00M 0.00M -
Net income from continuing ops -0.05M 0.16M -4.42M -1.17M -
Net income applicable to common shares -0.05M 0.16M -4.42M -1.17M -
Breakdown 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Total assets 1.80M 1.84M 2.04M 6.45M 7.15M
Intangible assets 0.00M 0.00M 0.00M 0.00M -
Other current assets 0.00M 0.00M -0.00M 0.00M 0.56M
Total liab 0.13M 0.12M 0.44M 0.40M 0.32M
Total stockholder equity 1.67M 1.72M 1.60M 6.05M 6.83M
Deferred long term liab 0.00M 0.00M 0.00M 0.00M -
Other current liab 0.00M 0.00M 0.00M 0.00M 0.09M
Common stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings -228.47M -228.42M -228.58M -224.16M -223.37M
Other liab 0.00M 0.00M 0.00M 0.00M -
Good will 0.00M 0.00M 0.00M 0.00M 0.22M
Other assets 1.59M 1.59M 1.59M 1.59M -
Cash 0.05M 0.02M 0.09M 0.10M 3.53M
Total current liabilities 0.13M 0.10M 0.44M 0.30M 0.32M
Net debt - - - - -3.53M
Short term debt 0.00M 0.02M 0.00M 0.11M -
Short long term debt 0.00M 0.02M 0.00M 0.11M -
Other stockholder equity 0.40M 0.40M 0.40M 0.40M 229.76M
Property plant equipment 0.03M 0.03M 0.03M 0.03M -
Total current assets 0.19M 0.23M 0.43M 0.31M 4.37M
Long term investments 0.00M 0.00M 0.00M 4.53M -
Net tangible assets 1.67M 1.72M 1.60M 6.05M -
Short term investments 0.00M 0.00M 0.00M 0.00M -
Net receivables 0.12M 0.19M 0.33M 0.16M 0.29M
Long term debt 0.00M 0.03M 0.00M 0.10M -
Inventory 0.00M 0.00M 0.00M 0.00M -
Accounts payable 0.12M 0.09M 0.28M 0.28M 0.23M
Total permanent equity 0.00M 0.00M 0.00M 0.00M -
Noncontrolling interest in consolidated entity 0.00M 0.00M 0.00M 0.00M -
Temporary equity redeemable noncontrolling interests 0.00M 0.00M 0.00M 0.00M -
Accumulated other comprehensive income 0.00M 0.00M 0.00M 0.00M 0.40M
Additional paid in capital 0.00M 0.00M 0.00M 0.00M -
Common stock total equity 0.00M 0.00M 0.00M 0.00M -
Preferred stock total equity 0.00M 0.00M 0.00M 0.00M -
Retained earnings total equity 0.00M 0.00M 0.00M 0.00M -
Treasury stock 0.00M 0.00M 0.00M 0.00M -
Non current assets total - - - - 2.78M
Breakdown 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2010-12-31
Investments 0.00M 0.00M 0.00M 0.00M -
Change to liabilities 0.04M -0.20M 0.01M -0.23M -
Total cashflows from investing activities 0.00M 0.00M 0.00M 0.00M -
Net borrowings 0.00M 0.00M 0.00M -1.27M -
Total cash from financing activities 0.00M -0.04M -0.04M -0.65M -
Change to operating activities -0.03M -0.12M 0.03M 0.64M -
Net income -0.05M 0.16M -4.42M -1.17M -0.69M
Change in cash 0.03M -0.06M -0.01M -1.31M -
Begin period cash flow - - - - 5.70M
End period cash flow - - - - 3.53M
Total cash from operating activities 0.02M -0.02M -0.01M -0.67M -2.17M
Depreciation 0.00M 0.00M 0.00M 0.17M 0.01M
Other cashflows from investing activities 0.00M 0.00M 0.00M 0.00M -
Dividends paid 0.00M 0.00M 0.00M 0.00M -
Change to inventory 0.00M 0.00M 0.00M 0.00M -
Change to account receivables 0.06M 0.14M -0.16M -0.09M -0.16M
Sale purchase of stock 0.00M 0.00M 0.00M 2.05M -
Other cashflows from financing activities 0.00M 0.00M 0.00M -1.27M -1.50M
Change to netincome 0.00M 0.00M 4.53M -0.00M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - - - - -1.51M
Other non cash items - - - - 0.01M
Free cash flow - - - - -2.17M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DGEN
Deltagen Inc
-
-%
0.00 - 21.93 3.57 - 0.01 0.12
ISRG
Intuitive Surgical Inc
-5.75
1.27%
445.88 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme
1.24
0.61%
204.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
3.80
3.90%
101.21 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
-1.36
0.69%
195.03 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Deltagen Inc

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.

1900 South Norfolk Street, San Mateo, CA, United States, 94403

650-345-7601

Name Title Year Born
Dr. Robert J. Driscoll CEO, Pres, Sec. & Director 1966
Mr. Daniel Ratto Chief Financial Officer 1958
Dr. Robert J. Driscoll J.D., Ph.D. CEO, President, Secretary & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…